Grantham Mayo Van Otterloo & Co. LLC Sells 59,350 Shares of Solventum Co. (NYSE:SOLV)

Grantham Mayo Van Otterloo & Co. LLC cut its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 10.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 494,160 shares of the company's stock after selling 59,350 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC owned 0.29% of Solventum worth $32,644,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Resona Asset Management Co. Ltd. purchased a new position in shares of Solventum during the fourth quarter valued at $3,029,000. Integrated Quantitative Investments LLC purchased a new position in Solventum during the 4th quarter valued at about $377,000. Atlas Capital Advisors Inc. acquired a new position in shares of Solventum in the 4th quarter valued at about $63,000. Motley Fool Asset Management LLC increased its holdings in shares of Solventum by 9.7% in the 4th quarter. Motley Fool Asset Management LLC now owns 3,781 shares of the company's stock valued at $250,000 after purchasing an additional 333 shares during the period. Finally, Geode Capital Management LLC lifted its position in shares of Solventum by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock worth $227,992,000 after purchasing an additional 112,686 shares in the last quarter.

Solventum Stock Up 0.3 %

Shares of SOLV traded up $0.22 during trading hours on Friday, hitting $65.39. 331,267 shares of the company were exchanged, compared to its average volume of 1,342,938. The firm's 50 day moving average is $74.36 and its 200-day moving average is $71.72. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a market cap of $11.31 billion and a PE ratio of 23.70.

Wall Street Analyst Weigh In

Several research firms have weighed in on SOLV. Piper Sandler upped their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a research note on Friday, February 28th. Wells Fargo & Company upped their price target on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Friday, February 28th. Mizuho lifted their price objective on Solventum from $70.00 to $82.00 and gave the company a "neutral" rating in a research report on Monday, March 3rd. Bank of America upped their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 26th. Finally, Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.